Highlights Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Pharmaceuticals

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 10:24:24 2025-07-17 am EDT			5-day change	1st Jan Change
1.200 ^ILa	-7.69%		-7.69%	-36.84%

Jun. 16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston	CI
May. 05	Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson	RE

Highlights

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston	Jun. 16	CI
Can-Fite Biopharma Ltd. Announces FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson	Apr. 17	CI
Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations	Apr. 14	MT
Can-Fite Reports 2024 Financial Results And Clinical Update	Apr. 14	RE
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 14	CI
Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication	Mar. 24	MT
Can-Fite BioPharma Ltd. Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol	Mar. 24	CI
Can-Fite BioPharma Ltd. Announces to Initiate Phase II Study in Rare Genetic Disease Lowe Syndrome with Piclidenoson	Mar. 19	CI
Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient	Mar. 18	MT
Can-Fite BioPharma Ltd. Receives Single FDA Approval for the Compassionate Use Treatment of U.S. Based Pancreatic Cancer Patient with its Anti-Cancer Drug Namodenoson	Mar. 18	CI
Can-Fite BioPharma Ltd. Announces US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug	Jan. 27	CI
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite?s anti-Cancer Drug Namodenoson	Dec. 30	CI
Can-Fite Biopharma Ltd. Announces 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite?s Namodenoson Drug	Dec. 04	CI
Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer	Nov. 11	MT
Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial	Nov. 11	CI
Can-Fite BioPharma's Partner Reports Positive Study Results of Piclidenoson in Dogs With Osteoarthritis	24-10-18	MT
Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson	24-10-18	CI
Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation	24-10-09	MT
Can-Fite BioPharma Ltd. and Vetbiolix Signs Development and Commercialization Agreement for the Development of Piclidenoson for the Treatment of Osteoarthritis in Companion Animals Including Dogs and Cats	24-09-24	CI
Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma	24-09-16	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-29	CI
Can-Fite BioPharma Ltd. Provides Namodenoson Patent Update	24-07-29	CI
Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	24-07-01	CI
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	24-06-28	CI
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	24-06-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Pharmaceuticals

Highlights

Filters